NEW YORK (GenomeWeb) – Elucigene Diagnostics, a maker of PCR-based molecular tests, is branching further into the reproductive health and in vitro fertilization markets with assays for recurrent pregnancy loss and Y-chromosome microdeletions that can cause male infertility.

The majority of the firm's tests use capillary electrophoresis instruments from Thermo Fisher's Applied Biosystems, Chris Jones, Elucigene's sales and marketing manager, told GenomeWeb in an interview this week.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In a statement, National Institutes of Health Director Francis Collins says sexual harassment is "morally indefensible" and "unacceptable."

Stat News and ProPublica report that African Americans are underrepresented in cancer clinical trials.

Octopuses might owe their intelligence to their liberal alterations to their genes, Cosmos reports.

In Cell this week: genomic analysis of abdominal aortic aneurysm, effect of probiotics on the microbiome, and more.

Oct
02
Sponsored by
Roche

In the last few years several molecular testing methodologies — such as immunohistochemistry, PCR, and sequencing — have been approved by the US Food and Drug Administration to aid in the management of patients with lung cancer.  

Oct
10
Sponsored by
Philips Genomics

This webinar will provide a first-hand look at how the Dana-Farber Cancer Center is adapting its oncology care strategy in light of the rapidly evolving molecular landscape.